BackJade Biosciences Overview
Jade Biosciences, Inc.

Jade Biosciences Target Price

See Jade Biosciences's analyst price targets ($44) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$21.87

Average Target Price

$44.13101.8% upside

8 analysts in the last 4 months

High: $55 | Low: $32

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-11Jefferies$48119.5% upsideOpen
2026-08-10WedbushLaura Chico$47114.9% upsideOpen
2026-06-15UBS$45105.8% upsideOpen
2026-06-02Piper Sandler$55151.5% upsideOpen
2026-06-02GuggenheimVamil Divan$47114.9% upsideOpen
2026-05-11WedbushLaura Chico$3455.5% upsideOpen
2026-05-11Guggenheim$3246.3% upsideOpen
2026-04-27H.C. Wainwright$45105.8% upsideOpen
2026-03-06Stifel NicolausAlex Thompson$4082.9% upsideOpen
2026-01-07H.C. Wainwright$2514.3% upsideOpen
2025-10-09BTIG$2828% upsideOpen
2025-06-16GuggenheimVamil Divan$1436% downsideOpen
2025-05-05Stifel NicolausAlex Thompson$1913.1% downsideOpen

Jade Biosciences (JBIO) FAQ

Jade Biosciences's target price stands at $44. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $44 for JBIO implies 101.8% upside versus today's price ($21.87). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Jade Biosciences's target price evolved across reporting periods, while the comparison chart places JBIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Jade Biosciences's reading of $44 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.